Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients
نویسندگان
چکیده
منابع مشابه
Oral direct factor Xa inhibitors.
Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its pharmacodynamics and metabolism. Consequently...
متن کاملComparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
OBJECTIVES A comparative analysis of three major clinical trials with factor Xa inhibitor oral anticoagulant (XOAC) drugs versus warfarin in atrial fibrillation-Rocket-AF (rivaroxaban), Aristotle (apixaban) and Engage AF Timi 48 (edoxaban; two different doses and sets of data)-was carried out. METHODS Data were extracted from the original reports (study level) and a meta-analysis was carried ...
متن کاملcontinuing education Oral , Direct Factor Xa Inhibitors and Thromboembolic Disorders
pon successful completion of this article, the pharmacist should be able to: 1. List the advantages and disadvantages of currently available anticoagulants. 2. Discuss the role of Factor Xa (FXa) in the coagulation cascade and the rationale for selected FXa inhibition as a target for drug development. 3. Discuss the pharmacology of apixaban and rivaroxaban: mechanism of action, pharmacokinetics...
متن کاملSafety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate the safety and efficacy of edoxaban in Asian patients with non-valvular AF with CHADS2 score ≥1. In a multicentre, active-controlled, double-blind edoxaban and open-label warfarin, parallel-group study...
متن کاملOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
BACKGROUND Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately 1 in 1,000 people. If left untreated, the clot can travel up to the lungs and cause a potentially life-threatening pulmonary embolism (PE). Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Advances
سال: 2018
ISSN: 2473-9529,2473-9537
DOI: 10.1182/bloodadvances.2017013805